Our technologies are based on a combination of fluorescence, fluorescence lifetime, and fluorescence anisotropy measurements, which allows the development of assays with high sensitivity and specificity and free of background interference.
By combining fluorescence measurements at the single molecular level together with immunochemistry and nanotechnology, we developed a generic platform for sensitive detection of biomarkers in a homogeneous format.
This technology could provide evidence-based medicine with affordable simple-to-use devices for biomarker testing in near-patient settings.
